Asset profile
RD01 (PEG-EPO)
Biologic (subtype unspecified)
Evidence outlook · results not reported
NCT04231292 · Patient of Anemia in Chronic Renal Failure With Hemodialysis
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT04231292: This is a randomized, controlled trial (active and placebo comparator arms) using hemoglobin concentration, the disease-defining measure for anemia, as its primary endpoint, but only participants were masked (not investigators or assessors), and no results have yet been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 59 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| RD01 (PEG-EPO): this drug | Phase 2 | Biologic (subtype unspecified) | Erythropoietin receptor (EPO-R) | ||
| JR-131 | Phase 3 | Biologic (subtype unspecified) | Erythropoietin receptor (EPO-R) | ||
| NNG-DEPO (Stimus) | Phase 3 | Biologic (subtype unspecified) | Erythropoietin receptor (EPO-R) | ||
| Pegmolesatide (HS-20039) | Phase 3 | Peptide | Erythropoietin receptor (EPO-R) | ||
| rESP | Phase 3 | Biologic (subtype unspecified) | Erythropoietin receptor (EPO-R) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.